Compensatory Mechanisms in Parkinson Disease (PD)

Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET

Parkinson's disease is characterized by a large number of non motor, especially neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and serotoninergic systems dysfunction is suggested by several studies. In addition, the serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies have analyzed the abnormalities of these two neurotransmission systems at disease onset, in de novo PD patients. Furthermore, the parallel evolution of the degeneration of the dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role of the serotoninergic and dopaminergic systems dysfunction in motor and non motor manifestations in PD, at different evolution stages.

Inclusion Criteria:

Patients

• Patients presenting doparesponsive Parkinson's disease
• Patient's age between 40 and 70 years old
• Absence of other neurological or psychiatric disease
• Absence of cognitive decline ( MATTIS > 130)
• For women of childbearing age a pregnancy test and a contraceptive method will be required
• Informed consent sign

Healthy subjects

• subject's age between 40 and 70 years old
• Absence of neurological or psychiatric disease
• Absence of cognitive decline ( MATTIS > 130)
• For women of childbearing age a pregnancy test and a contraceptive method will be required
• Informed consent sign

Exclusion Criteria:

Patients

• patient's age < 40 years old or > 70 years old
• Other neurological or psychiatric disease
• Cognitive decline (MATTIS < 130).
• Having participated to a PET or SPECT study in the last 12 months
• Pregnancy
• Severe concomitant disease

Healthy subjects

• subject's age < 40 years old or > 70 years old
• Neurological or psychiatric disease
• Cognitive decline (MATTIS < 130).
• Having participated to a PET or SPECT study in the last 12 months
• Pregnancy
• Severe concomitant disease